ClearPoint Neuro (NASDAQ:CLPT) Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPS

ClearPoint Neuro (NASDAQ:CLPT) posted its quarterly earnings results on Wednesday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05), Zacks reports. The company had revenue of $7.77 million during the quarter, compared to analyst estimates of $8.23 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. ClearPoint Neuro updated its FY 2025 guidance to EPS.

ClearPoint Neuro Stock Performance

Shares of NASDAQ CLPT traded down $2.35 during trading on Thursday, hitting $14.87. The company had a trading volume of 114,907 shares, compared to its average volume of 200,182. The company has a market cap of $410.19 million, a P/E ratio of -21.35 and a beta of 1.03. ClearPoint Neuro has a 52 week low of $5.11 and a 52 week high of $19.22. The business’s 50-day moving average is $16.67 and its 200 day moving average is $13.80.

Analysts Set New Price Targets

Several research firms have recently commented on CLPT. B. Riley upped their price target on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Lake Street Capital upped their target price on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, January 21st.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.